Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conferenceseries Ltd: World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Euro Oncology 2018

About Conference


Conference Series invites all the oncologists and the cancer researchers across the globe to attend the much awaited 37th Annual Euro Oncology Summit 2018 (Euro Oncology-2018) scheduled on October 18- 19, 2018 at Amsterdam, Netherlands, which is the part of our Oncology Series Conferences.

The Annual Euro Oncology Summit aims to brings together the oncology researchers, oncologists, oncology surgeons, surgical oncologists, radiologists, oncology pathologists, pathologists, immune oncology therapist, nurses, health workers,  multidisciplinary oncology specialists or oncologists working in the area of various organ specific cancers like: Breast Cancer, Colorectal Cancer, Colon Cancer, Brain tumours, blood cancers, urological cancer specialists, lung cancer specialists etc. The Cancer Experts to be gather here are basically from industry, hospitals, cancer centres and academia with the aim to discuss the current issues, trends including future innovations and strategies in the broad arena of Cancer research.

Our Europe Oncology Series Conferences comprise of Plenary sessions, Keynote sessions, Oncology expert meetings, Oral presentations, Poster Presentations, industrial presentations, One to one meetings, B2B meetings, Panel discussions, round table meetings, Young researcher Forums (YRF), International workshops, Exhibitor presentations, Sponsor interactions, International Symposiums, Young Scientist awards etc. The Euro Oncology Summit comes up with Young Researcher/ Young Scientist awards to felicitate the young researchers and research scholars in an international platform and to flourish the young minds.

The scope of conference covers all fields of cancers. The sessions are designed in such a way that, it will cover the current trends and challenges in the diagnosis, treatment and management of all cancer types, but not limited to: Acute Lymphoblastic Leukaemia (ALL)

Acute Myeloid Leukaemia (AML), Adrenocortical Carcinoma, Anal Cancer, Basal and Squamous Cell Skin Cancer, Bile Duct Cancer, Bladder Cancer, Bone Cancer, Brain and Spinal Cord Tumors, Breast Cancer, Castleman Disease, Cervical Cancer, Chronic Lymphocytic Leukaemia (CLL), Chronic Myeloid Leukaemia (CML), Chronic Myelomonocytic Leukaemia (CMML), Colorectal Cancer, Ductal Carcinoma In Situ (DCIS), Endometrial Cancer, Oesophagus Cancer, Ewing Family of Tumors, Eye Cancer, Fallopian Tube Cancer, Fibrous Histiocytoma of Bone, Malignant, and Osteosarcoma, Gallbladder Cancer Gastrointestinal Carcinoid Tumors, Gastrointestinal Stromal Tumor (GIST),  Hodgkin Lymphoma, Head and Neck Cancer, Hepatocellular (Liver) Cancer, Histiocytosis, Langerhans Cell, Hypo pharyngeal Cancer, Intraocular Melanoma, Islet Cell Tumors, Pancreatic Neuroendocrine Tumors, Kaposi Sarcoma, Laryngeal and Hypo pharyngeal Cancer,  Leukaemia, Liver Cancer, Lung Cancer, Lung Carcinoid Tumor, Lymphoma, Lymphoma of the Skin, Melanoma Skin Cancer, Merkel Cell Skin Cancer, Multiple Myeloma, Myelodysplastic Syndromes, Nasal Cavity and Paranasal Sinuses Cancer Nasopharyngeal Cancer, Neuroblastoma, Non-Hodgkin Lymphoma, Lung Cancer, Oral Cavity and Oropharyngeal Cancer, Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Penile Cancer, Pituitary Tumors, Prostate Cancer, Plasma Cell Neoplasm/Multiple Myeloma, Pheochromocytoma, Paranasal Sinus and Nasal Cavity Cancer, Pancreatic Neuroendocrine Tumors (Islet Cell Tumors), Rectal Cancer, Renal Cell (Kidney) Cancer, Retinoblastoma, etc.

Conference Highlights:

  • Organ Specific Cancer
  • Cancer and cell cycle/ Cell cycle in Cancer
  • Cancer Pathology
  • Carcinogenesis and Mutagenesis
  • Oncogenomics/Cancer Genetics and Epigenetics
  • Cancer Immunotherapy and Immunooncology
  • Cancer Epidemiology, Screening & Prevention
  • Biomarker application in Cancer
  • Microbiome and Cancer
  • Neonatal and Pediatric Oncology
  • Radiology and Cancer Imaging
  • Cancer Diagnosis
  • Targeted Anticancer Therapy
  • Surgical Oncology
  • Oncology Nursing
  • Therapeutic Anti-Cancer Vaccines
  • Oncology and Palliative care
  • Advanced technologies and cancer
  • Complementary and Alternative Medicine
  • Clinical Trials and Cancer
  • Oncology and Nutrition
  • Cancer Case Reports
  • Metastasis and Drug Resistance
  • New Cancer Drug development
  • Solid Tumor Oncogenesis

Why To Attend

  • Oncology workshop/ Symposium, B2B and interactive sessions, CME Meetings, with industry Sponsors and Exhibitors
  • World-class platform to exhibit your products and services in the field of Oncology
  • Meet the Oncologists from 25+ countries across the globe
  • Interactive panel discussions and Q&A sessions
  • Earn up to 21 CME/ CPD credits
  • Live network and interaction with industry Sponsors/ experts
  • Well organizing scientific program with 5+ hours of networking sessions
  • Meet with key decision makers in the Oncology industry worldwide and learn about the latest innovations, technologies, trends and developments in Cancer industry
  • Best Poster Award/ Young Research Forum.

Who Should Attend

The Euro Oncology Meeting 2018, Amsterdam, Netherlands offers a platform for the Oncologists and experts both from Industry and Academia working in various sub domains of Oncology ranging from classical Oncology to the advanced technologies and image analysis in Oncology including Oncological Diagnosis and therapy.

Professionals from Oncological Laboratories, Hospitals, and Academics:

Directors, Deans, Research Professionals, Laboratory heads, Lab managers, Lab technicians, Laboratory Professionals, Medical/ Biomedical scientists, Professors, Associate Professors, Assistant Professors, Research Practicing pathologist, Research Fellows, Medical students, Nurses, Residents, working in the arena of Oncology and its allied fields,

but not limited to:

  • Acute Lymphoblastic Leukaemia (ALL)
  • Breast Cancer
  • Melanoma Skin Cancer
  • Non-Hodgkin Lymphoma
  • Renal Cell (Kidney) Cancer
  • Lung Cancer
  • Prostate Cancer
  • Bone Cancer
  • Liver Cancer
  • Brain and Spinal Cord Tumors etc.

Industry partners and professionals, vendors in the arena of :

  • Oncology
  • Diagnostic Devices
  • Imaging Products
  • Oncology Lab Equipment manufacturers
  • Commercial Diagnostics laboratories
  • Clinical Research Organizations (CRO)
  • Lab reagents, Assays and Kits suppliers
  • Oncology service providers etc.
  • Leading companies with Clinical laboratory/ Oncology Services
  • Genomic Health
  • Bio-Reference Laboratories
  • Alere
  • Laboratory Corporation of America
  • Myriad Genetics
  • NeoGenomics
  • Quest Diagnostics
  • Siemens Healthineers
  • Sonic Healthcare Limited
  • Spectra Laboratories
  • SYNLAB International GMBH

Top Oncology Therapies:

  • Rituxan
  • Avastin
  • Alimta
  • Xeloda
  • Tarceva
  • Zometa
  • Sutent
  • Nexavar
  • Revlimid
  • Opdivo
  • Imbruvica
  • Keytruda
  • Ibrance
  • Tecentriq
  •  Darzalex
  •  Perjeta
  •  Xtandi
  •  Herceptin
  •  Gazyva
  •  Jakafi
  •  Venclexta

Session/Tracks

Oncology

Oncology is a branch of science that deals with the diagnosis, prevention and treatment of cancer.

The three mechanisms which have enhanced the survival in Cancer are:

1.      Prevention- By reducing the risk factors like tobacco and alcohol consumption

2.      Diagnosis- Screening of cancer, diagnosis and staging

3.      Treatment- It can be treated by chemotherapy, hormonal therapy, targeted therapy (including immunotherapy such as monoclonal antibody therapy), synthetic lethality and surgery.

Track 1: Organ Specific Cancer

Cancer is one of the leading cause of deaths across the world. Organ Specific Cancers are cancers named basing on the site of cancer in the body organ. Its incidence is showing an increasing tendency in various parts of the earth and has been a significant public health problem despite advances in the understanding of the molecular and cellular events that underlie.

There are different types of cancers based on location of cancer in the body organ. For example: Brain cancer, Head and Neck Cancer, Oral cancer, Lung cancer, Liver cancer, Breast cancer, Prostate cancer, Gastric cancer, Pancreatic cancer, Kidney (Renal Cell) cancer, Leukaemia etc. These types of malignancies come under the category of Organ Specific Cancer.

  • Thyroid Cancer                      
  • Non-Hodgkin Lymphoma
  • Lung Cancer
  • Pancreatic Cancer
  • Melanoma
  • Prostate Cancer
  • Endometrial Cancer
  • Bladder Cancer

Track 2: Cancer and cell cycle/ Cell cycle in Cancer

Cancer cells are the cells that divide continuously which flood the blood with abnormal cells and forms solid tumours. Cell division is a normal utilised by the body for growth and repair. A parent cell divides to form 2 daughter cells which are used to build a new tissue or to replace dead cells as a result of damage or ageing. Cancer cells continue to produce copies where the healthy cells stop dividing as there is a no longer need for more daughter cells. Cancer cells have capability of spreading from one part of the body to another in a process known as metastasis.

  • Oncogenes
  • Tumor suppressors
  • Apoptosis

Track 3: Cancer Pathology

Pathology is vital to cancer diagnosis, treatment and research. Developments in pathology during the 20th century enabled more precise concepts to evolve and be adopted in clinical practice: cancer grading and staging, carcinoma in situ, cytopathology in screening and diagnosis, immunohistochemistry and biomarkers.

As we enter the 21st century, cancer is acknowledged as a genetic disease that can be diagnosed and treated using molecular/genomic approaches in addition to traditional surgery, radiotherapy and chemotherapy. Another wave of technologic advances in digitization, telepathology, molecular diagnostics and genomic screening marks the latest paradigm shift in cancer pathology.

  • Centralization and telepathology
  • Cytopathology
  • Molecular pathology

Track 4: Carcinogenesis and Mutagenesis

Carcinogenesis is also called as tumorigenesis or oncogenesis. It is the formation of cancer where the normal cells are transformed into the cancer cells. The process is characterized by changes in the abnormal cell division, cellular, genetic, and epigenetic levels. Cell division is a physiological procedure that occurs in all tissues. Normally the balance between proliferation and automatic cell death, in the form of apoptosis, is maintained to ensure the consistency of tissues and organs.

Mechanism of Carcinogenesis

  • Oncogenes
  • Proto-oncogenes
  • Tumor suppressor genes
  • Multiple mutations
  • Non-mutagenic carcinogens

Mutagenesis is a method by which the genetic information of an organism is altered, resulting in a mutation. DNA may be altered either naturally or artificially by using physical, chemical and biological agents which results in mutations. Mutagen generally changes the genetic material of DNA of an organism and increases the occurrence of mutation and increased level of mutations cause cancer. Some of the chemicals become mutagenic only through cellular processes and all the mutations are not caused by mutagens: “spontaneous mutations” occur due to hydrolysis, errors in DNA replication, repair and recombination.

Types of Mutagens

  • Physical mutagens
  • DNA reactive chemicals
  • Base analogues
  • Intercalating agents
  • Metals
  • Biological agents

Track 5: Oncogenomics/Cancer Genetics and Epigenetics

Cancer is basically a disease of tissue growth regulation. In order for a normal cell to transform into a cancer cell, the genes that regulate cell growth and differentiation must be altered. The affected genes are divided into two broad categories: Oncogenes and Tumor suppressor genes. Oncogenes are genes that stimulate cell growth and reproduction. Tumor suppressor genes are genes that inhibit cell division and survival. Malignant transformation can occur through the development of novel oncogenes, the inappropriate over-expression of usual oncogenes, or by the under-expression or disabling of tumor suppressor genes. Typically, alterations in multiple genes are required to transform a normal cell into a cancer cell.

  • Genomics Technologies
  • Comparative oncogenomics
  • Gene families
  • Mitochondrial DNA
  • Cancer biomarkers
  • Source of cancer driver mutations, cancer mutagenesis

Cancer epigenetics deals with the epigenetic modifications to the genome of cancer cells that do not involve any change in the nucleotide sequence. Epigenetic alterations are as vital as genetic mutations in a normal cell transformation to cancer cells, and their manipulation holds great promise for cancer prevention, detection, and therapy. In different types of cancer, a variety of epigenetic mechanisms can be perturbed, such as silencing of tumor suppressor genes and activation of oncogenes by altered CpG island methylation patterns, histone modifications, and dysregulation of DNA binding proteins. Several medications which have epigenetic impact are now used in several of these diseases.

  • DNA methylation in Cancer
  • Histone modification
  • MicroRNA gene silencing
  • MicroRNA and DNA repair
  • DNA repair pathways
  • Frequencies of epimutations in DNA repair genes
  • Epigenetic carcinogens

Track 6: Cancer Immunotherapy and Immunooncology

Cancer immunology is a division of biology involved in understanding the role of the immune system in progression, advancement and the expansion of cancer the most well recognized application is cancer immune therapy, which uses the immune system as a treatment for cancer.

Cancer immunology interacts between the immune system and tumours or distortions.

Recognition of Cancer Specific Antigens

1. Immunosurveillance

  • Lymphocytes act as sentries in recognizing and eliminating continuously arising, nascent transformed cells

2. Immunoediting

  • Process by which a individual is endangered from cancer growth and the development of malignancy immunogenicity

I. Elimination

II. Equilibrium

III. Escape

  • Personalized Immunotherapy
  • Immune Profiling in Cancer
  • Combination Immunotherapy
  • Next Gen CAR-T Cell therapy
  • Pre-clinical and Translational Immuno-Oncology Developments
  • Check Point Inhibitors and Combination Strategies
  • Novel Payloads and Linkers
  • Oncolytic viruses in the era of checkpoint blockade
  • Personalized Immunotherapy and Viral Therapies
  • Novel concepts in Bispecific Antibodies Engineering
  • Tumor Microenvironment

Track 7: Cancer Epidemiology, Screening & Prevention

The epidemiology of cancer is the study of the factors affecting cancer, as a way to conclude possible trends and causes. The study of cancer epidemiology uses epidemiological methods to discover the cause of cancer and to recognize and develop improved treatments. This area of study must cope with problems of lead time bias and length time bias. Lead time bias is the theory that early diagnosis may artificially inflate the survival statistics of a cancer, without really improving the natural history of the disease. Length bias is the concept that gentler growing, more lethargic tumors are more likely to be identified by screening tests, but improvements in diagnosing more cases of indolent cancer may not translate into better patient outcomes after the implementation of screening programs.

  • Statistical analysis
  • Risk factors
  • Mortality Rate

Prevention or Preventive healthcare means measures that are taken for cancer prevention. Cancer can be prevented by living a healthy lifestyle. A healthy lifestyle and regular screening exams help to reduce your risk for some types of cancer.

Screenings can find cancer early, when it’s most treatable. Cancer screening aims to identify cancer before symptoms appear. This may involve blood tests, urine tests, other tests, or medical imaging. The benefits of screening in terms of cancer prevention, early detection and subsequent treatment must be weighed against any harm. Worldwide screening, population screening or mass screening involves screening everyone, generally within a specific age group. Selective screening identifies people who are known to be at advanced risk of developing cancer, such as people with a family history of cancer.

  • Benefits and potential harms of screening
  • Screening considerations by age group
  • Frequency of screening
  • Clinical examination (CE)

Market Analysis

To Collaborate Scientific Professionals around the World

Conference Date October 18-19, 2018

For Sponsors & Exhibitors

[email protected]

Speaker Opportunity

Past Conference Report

Supported By

Journal of Cancer Science & Therapy Journal of Cancer Research and Immuno-Oncology International Journal of Inflammation, Cancer and Integrative Therapy Journal of Oncology Medicine & Practice

All accepted abstracts will be published in respective Conferenceseries International Journals.

Abstracts will be provided with Digital Object Identifier by